Leadership, Board & Advisors
Leadership
-
Antal Szalay MD, MBA
Founding physician-scientist CEO advancing first-in-class gut–brain metabolite therapeutics, co-inventor of foundational IP published in Nature Aging and Nature Neuroscience.
-
Jerry Clifford, PhD, MBA
Senior strategy and commercialization executive with 20+ years across biotech and life sciences, former Danaher innovation executive and multi-venture founder with €200M+ in cumulative exit value
-
Kevin McAllister, PhD, MBA
CNS drug development veteran with 25+ years advancing neuroscience programs from discovery through Phase 2, including multiple clinical proofs-of-concept at Novartis.
-
Lauren Moores, PhD
Data and AI executive building scalable information systems and data products, bringing 25+ years of cross-industry experience applying emerging technologies to high-complexity domains.
-
Belén Fortes, MBA
Strategic programs leader with a proven track record of securing $70M+ in biotech funding and driving execution from development through commercialization.
-
Christophe Loeffler, MSC
Finance and operations leader with 30+ years of experience scaling startups, overseeing accounting, tax, compliance, and international corporate structures.
Advisor Board
-
Preston Campbell III, MD
BOARD ADVISOR
Visionary physician-leader and former CEO of the Cystic Fibrosis Foundation who enabled 12 FDA-approved therapies and pioneered the venture-philanthropy model for drug development. -
Robert Gallato
BOARD ADVISOR
Seasoned biotech entrepreneur with 30+ years leading rare-disease companies from inception to market, including award-winning device development and successful venture-philanthropy partnerships.
Science Advisory Board
-
Ted Torphy, PhD
Veteran biopharma executive and serial board member with 35+ years advancing blockbuster therapeutics and shaping drug discovery strategy across pharma, biotech, and venture-backed companies.
-
Michael Weiner, MD
Global Alzheimer’s research leader and ADNI founder whose biomarker and imaging frameworks underpin the majority of modern AD clinical trials and regulatory decisions.
-
Rainer Reidl, PhD
Distinguished medicinal chemist and Head of Drug Discovery at ZHAW with 25+ years of Big Pharma and academic experience, securing €15M+ in competitive funding across antiviral, antimicrobial, and oncology programs.
-
Hansruedi Loetscher, PhD
SCIENCE ADVISOR
Former Global Head of Neuroscience Discovery at Roche and seasoned board-level advisor with decades of experience advancing Alzheimer’s therapeutics from discovery through late-stage clinical development.
-
Thomas Blank, PhD
Co-discoverer of novel metabolic pathways underlying neurodegeneration, forming the scientific basis for Ultimate Medicine’s small-molecule strategy to block toxic metabolite synthesis and restore neuronal function.